Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Cash from Financing Activities: 2010-2025

Historic Cash from Financing Activities for Altimmune (ALT) over the last 15 years, with Sep 2025 value amounting to $39.3 million.

  • Altimmune's Cash from Financing Activities rose 14692.86% to $39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $135.8 million, marking a year-over-year increase of 86.76%. This contributed to the annual value of $10.0 million for FY2024, which is 88.34% down from last year.
  • Altimmune's Cash from Financing Activities amounted to $39.3 million in Q3 2025, which was down 24.68% from $52.2 million recorded in Q2 2025.
  • In the past 5 years, Altimmune's Cash from Financing Activities ranged from a high of $72.8 million in Q4 2023 and a low of -$302,000 during Q1 2023.
  • Over the past 3 years, Altimmune's median Cash from Financing Activities value was $10.1 million (recorded in 2024), while the average stood at $20.2 million.
  • The largest annual percentage gain for Altimmune's Cash from Financing Activities in the last 5 years was 169,295.35% (2023), contrasted with its biggest fall of 109.49% (2023).
  • Altimmune's Cash from Financing Activities (Quarterly) stood at $12.5 million in 2021, then crashed by 100.34% to -$43,000 in 2022, then soared by 169,295.35% to $72.8 million in 2023, then plummeted by 86.14% to $10.1 million in 2024, then soared by 14,692.86% to $39.3 million in 2025.
  • Its Cash from Financing Activities was $39.3 million in Q3 2025, compared to $52.2 million in Q2 2025 and $34.1 million in Q1 2025.